FDA recognition accelerates development of first-in-class mitochondrial cell therapy for ultra-rare pediatric disorder

Minovia Therapeutics has received Fast Track and Rare Pediatric Disease (RPD) designations from the US Food and Drug Administration (FDA) for its lead candidate, MNV-201.

The investigational therapy is currently in Phase 2 development for Pearson Syndrome — a severe and life-threatening mitochondrial disorder that affects children.

The dual designation marks a significant milestone for the Israel-based company’s mitochondrial augmentation platform. MNV-201 is a first-in-class cell therapy designed to restore mitochondrial function by delivering healthy mitochondria into a patient’s own stem cells, potentially improving multi-system health and organ function.

Fast Track Designation is intended to expedite the development and review of treatments for serious conditions with unmet need, offering more frequent FDA interactions, rolling submissions, and potential priority review.

The Rare Pediatric Disease Designation also opens the possibility of receiving a priority review voucher (PRV) if the therapy is approved — a benefit historically valued highly in the biotech sector, though the PRV program is currently on pause pending reauthorization by Congress.

“This recognition strongly validates our clinical approach and the urgent need for new treatment options in Pearson Syndrome,” said Natalie Yivgi-Ohana, PhD, Minovia’s co-founder and CEO.

“These FDA designations help us decrease the potential time to market and provide added regulatory and financial benefits.”

Pearson Syndrome is caused by large-scale deletions in mitochondrial DNA, leading to energy production failure, bone marrow dysfunction, and often fatal outcomes in childhood. With no approved treatments, current care remains entirely supportive.

Minovia is currently running a Phase 2 clinical trial for MNV-201 and is in discussions with the FDA to finalize a pivotal trial design, with registrational studies expected to begin in 2026.

The company also recently announced a planned business combination with Launch One Acquisition Corp, a US-based SPAC. Following completion of the deal, expected later this year, Minovia will become a publicly traded company on Nasdaq.